Bazsa , This is only 6 months ago , the last paragraph answers a few questions, let’s keep in mind Lonza Has 11 Manufacturing stem cell centres world wide ...................................................................................
Allogeneic cellular medicines company Mesoblast (ASX: MSB) is on track to commence manufacturing of its lead product candidate remestemcel-L courtesy of a manufacturing agreement with Swiss-listed chemicals and biotechnology company Lonza (SWX: LONN).
Remestemcel-L is being developed for the treatment of acute graft versus host disease (aGVHD) following an allogeneic bone marrow transplant (BMT).
In a statement to the market, Mesoblast said the agreement between the two companies will facilitate inventory build ahead of a planned US market launch of remestemcel-L and ON GOING commercial supply to meet Mesoblast’s long-term market projections....
MSB Trading - 2020, page-12859
-
- There are more pages in this discussion • 10,302 more messages in this thread...
This thread is closed.
You may not reply to this discussion at this time.
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add MSB (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$1.45 |
Change
-0.030(2.03%) |
Mkt cap ! $1.655B | |||
| Open | High | Low | Value | Volume |
| $1.48 | $1.51 | $1.43 | $6.613M | 4.498M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 2482 | $1.45 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $1.46 | 27045 | 2 |
View Market Depth
| Last trade - 16.10pm 18/10/2024 (20 minute delay) ? |
| MSB (ASX) Chart |